You are here

American Journal of Cancer Prevention

ISSN (Print): 2328-7322

ISSN (Online): 2328-7314

Editor-in-Chief: Nabil Abdel-Hamid

Website: http://www.sciepub.com/journal/AJCP

   

Article

Percutaneous Radiofrequency Ablation versus Surgical Resection for the Treatment of Small Hepatic Carcinoma: A Meta-analysis

1Department of surgery, Dadukou District People’s Hospital, Chongqing, China

2Department of Hepatobiliary, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China

32Department of Hepatobiliary, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China


American Journal of Cancer Prevention. 2016, 4(1), 13-17
doi: 10.12691/ajcp-4-1-3
Copyright © 2016 Science and Education Publishing

Cite this paper:
Li Xin, Yun-bing Wang, Jian-ping Gong. Percutaneous Radiofrequency Ablation versus Surgical Resection for the Treatment of Small Hepatic Carcinoma: A Meta-analysis. American Journal of Cancer Prevention. 2016; 4(1):13-17. doi: 10.12691/ajcp-4-1-3.

Correspondence to: Jian-ping  Gong, 2Department of Hepatobiliary, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. Email: gongjianping11@126.com

Abstract

Aims: To evaluate the curative effect of percutaneous radiofrequency ablation (PRFA) versus surgical resection (SR) for the treatment of small hepatic carcinoma. Methods: Cochrane Library, Medline, Pubmed, CNKI, WanFang, VIP databases were searched from January 1990 to March 2013, then clinical control studies comparing curative effects of PRFA with SR in treatment of small hepatic carcinoma were acquired and reviewed. Qualities of these studies were evaluated. Publication bias was also assessed by using a funnel plot. Then primary outcomes, namely overall survival rates, disease-free survival rates and postoperative complication, were abstracted to conduct a combined analysis by using fixed or random effects model. Results: A total of eight studies involving 1287 patients were included in our study. The PRFA group has a lower overall survival rates over the SR group in 1 year (OR, 0.62; 95% confidence interval [CI], 0.43-0.89; P = 0.009), 3 years (OR, 0.44; 95% CI, 0.27-0.72; P=0.001), and 5 years (OR, 0.49; 95% CI, 0.35-0.68; P<0.0001). The PRFA group has a lower disease-free survival rates over the SR group in 1 year (OR, 0.63; 95% CI, 0.49-0.82; P=0.0006), 3 years (OR, 0.45; 95% CI, 0.30-0.67; P=0.0001), and 5 years (OR, 0.46; 95% CI, 0.33-0.64; P<0.00001). The postoperative complication of the PRFA group was lower than the SR group (OR, 0.21; 95% CI, 0.08-0.56; P<0.00001). Conclusion: PRFA had lower overall survival rates after surgery and disease-free survival than SR, but it has a lower incidence of postoperative complications. Then PRFA, acted as an operation with smaller invasion and shorter hospitalization time, would be a good choice for the patients with hepatic carcinoma who is reluctant to be treated by SR.

Keywords

References

[1]  Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM, “Estimates of worldwide burden of cancer in 2008: Globocan 2008,” Int J Cancer, 127(12), 2893-2917, 2010.
 
[2]  Forner A, Llovet JM, Bruix J, “Hepatocellular carcinoma,” Lancet, 379(9822) , 1245-1255, 2012.
 
[3]  De Lope CR, Tremosini S, Forner A, Reig M, Bruix J. “Management of hcc,” J Hepatol, 56 Suppl 1(S75-87), 2012.
 
[4]  El-Serag HB. “Hepatocellular carcinoma,” N Engl J Med, 365(12), 1118-1127, 2011.
 
[5]  Bruix J, Sherman M, “Management of hepatocellular carcinoma: An update,” Hepatology, 53(3), 1020-1022, 2011.
 
Show More References
[6]  Zarrinpar A, Kaldas F, Busuttil RW. “Liver transplantation for hepatocellular carcinoma: An update,” Hepatobiliary Pancreat Dis Int, 10(3), 234-242, 2011.
 
[7]  Llovet JM, Bruix J. “Novel advancements in the management of hepatocellular carcinoma in 2008,” J Hepatol, 48 Suppl 1(S20-37), 2008.
 
[8]  Benson AB 3rd, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, Covey A, Curley SA, D'Angelica MI, Davila R, Ensminger WD, Gibbs JF, Laheru D, Malafa MP, Marrero J, Meranze SG, Mulvihill SJ, Park JO, Posey JA, Sachdev J, Salem R, Sigurdson ER, Sofocleous C, Vauthey JN,Venook AP, Goff LW, Yen Y, Zhu AX. “Nccn clinical practice guidelines in oncology: Hepatobiliary cancers,” J Natl Compr Canc Netw, 7(4), 350-391, 2009.
 
[9]  Huo TI, Huang YH, Huang HC, Wu JC, Lee PC, Chang FY, Lee SD. “Fever and infectious complications after percutaneous acetic acid injection therapy for hepatocellular carcinoma: Incidence and risk factor analysis,” J Clin Gastroenterol, 40(7) , 639-642, 2006.
 
[10]  Zhang YY, Xia HH. “Novel therapeutic approaches for hepatocellulcar carcinoma: Fact and fiction,” World J Gastroenterol, 14(11) , 1641-1642, 2008.
 
[11]  Ni S, Liu L, Shu Y. “Sequential transcatheter arterial chemoembolization, three-dimensional conformal radiotherapy, and high-intensity focused ultrasound treatment for unresectable hepatocellular carcinoma patients,” J Biomed Res, 26(4), 260-267, 2012.
 
[12]  Cha DI, Lee MW, Rhim H, Choi D, Kim YS, Lim HK. “Therapeutic efficacy and safety of percutaneous ethanol injection with or without combined radiofrequency ablation for hepatocellular carcinomas in high risk locations,” Korean J Radiol, 14(2), 240-247, 2013.
 
[13]  Xue T, Le F, Chen R, Xie X, Zhang L, Ge N, Chen Y, Wang Y, Zhang B, Ye S, Ren Z. “Transarterial chemoembolization for huge hepatocellular carcinoma with diameter over ten centimeters: A large cohort study,” Med Oncol, 32(3), 64, 2015.
 
[14]  Huang J, Yan L, Cheng Z, Wu H, Du L, Wang J, Xu Y, Zeng Y. “A randomized trial comparing radiofrequency ablation and surgical resection for hcc conforming to the milan criteria,” Ann Surg, 252(6), 903-912, 2010.
 
[15]  Abu-Hilal M, Primrose JN, Casaril A, McPhail MJ, Pearce NW, Nicoli N. “Surgical resection versus radiofrequency ablation in the treatment of small unifocal hepatocellular carcinoma,” J Gastrointest Surg, 12(9), 1521-1526, 2008.
 
[16]  Ueno S, Sakoda M, Kubo F, Hiwatashi K, Tateno T, Baba Y, Hasegawa S, Tsubouchi H. “Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the milan criteria,” J Hepatobiliary Pancreat Surg, 16(3) , 359-366, 2009.
 
[17]  Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, Lin XJ, Lau WY. “A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma,” Ann Surg, 243(3), 321-328, 2006.
 
[18]  Lü MD, Kuang M, Liang LJ, Xie XY, Peng BG, Liu GJ, Li DM, Lai JM, Li SQ. “Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: A randomized clinical trial,” Zhonghua yi xue za zhi, 86(12), 801-805, 2006.
 
[19]  Feng K, Yan J, Li X, Xia F, Ma K, Wang S, Bie P, Dong J. “A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma,” J Hepatol, 57(4), 794-802, 2012.
 
[20]  Vivarelli M, Guglielmi A, Ruzzenente A, Cucchetti A, Bellusci R, Cordiano C, Cavallari A. “Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver,” Ann Surg, 240(1), 102-107, 2004.
 
[21]  Tohme S, Geller DA, Cardinal JS, Chen HW, Packiam V, Reddy S, Steel J, Marsh JW, Tsung A. “Radiofrequency ablation compared to resection in early-stage hepatocellular carcinoma,” HPB (Oxford), 15(3), 210-217, 2013.
 
[22]  Mazzaferro V, Chun YS, Poon RT, Schwartz ME, Yao FY, Marsh JW, Bhoori S, Lee SG. “Liver transplantation for hepatocellular carcinoma,” Ann Surg Oncol, 15(4), 1001-1007, 2008.
 
[23]  Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. “Assessing the quality of reports of randomized clinical trials: Is blinding necessary?,” Control Clin Trials, 17(1), 1-12, 1996.
 
[24]  Yim SY, Seo YS, Jung CH, Kim TH, Lee JM, Kim ES, Keum B, Jong YK, An H, Kim JH, Yim HJ, Kim DS, Jeen YT, Yeon JE, Lee HS,Chun HJ, Byun KS, Um SH, Kim CD, Ryu HS. “The management and prognosis of patients with hepatocellular carcinoma: What has changed in 20 years?,” Liver Int, 2015. [Epub ahead of print]
 
[25]  Zuo C, Xia M, Wu Q, Zhu H, Liu J, Liu C. “Role of antiviral therapy in reducing recurrence and improving survival in hepatitis b virus-associated hepatocellular carcinoma following curative resection (review) ,” Oncol Lett, 9(2), 527-534, 2015.
 
[26]  Weis S, Franke A, Berg T, Mössner J, Fleig WE, Schoppmeyer K. “Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma,” Cochrane Database Syst Rev, 1, CD006745, 2015.
 
[27]  Wang C, Wang H, Yang W, Hu K, Xie H, Hu KQ, Bai W, Dong Z, Lu Y, Zeng Z, Lou M, Wang H, Gao X, Chang X, An L, Qu J, Li J, Yang Y. “Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma,” Hepatology, 61(5), 1579-1590, 2015.
 
[28]  Kudo M. “Radiofrequency ablation for hepatocellular carcinoma: Updated review in 2010,” Oncology, 78 (Suppl 1), 113-124, 2010.
 
[29]  Stadlbauer V, Lang-Olip I, Leber B, Mayrhauser U, Koestenbauer S, Tawdrous M, Moche M, Sereinigg M, Seider D, Iberer F, Wiederstein-Grasser I, Portugaller RH, Stiegler P. “Immunohistochemical and radiological characterization of wound healing in porcine liver after radiofrequency ablation,” Histol Histopathol, 31(1), 115-129, 2016.
 
[30]  Ansari D, Andersson R. “Radiofrequency ablation or percutaneous ethanol injection for the treatment of liver tumors,” World J Gastroenterol, 18(10), 1003-1008, 2012.
 
[31]  Wakai T, Shirai Y, Suda T, Yokoyama N, Sakata J, Cruz PV, Kawai H, Matsuda Y, Watanabe M, Aoyagi Y, Hatakeyama K. “Long-term outcomes of hepatectomy vs percutaneous ablation for treatment of hepatocellular carcinoma < or =4 cm,” World J Gastroenterol , 12(4), 546-552, 2006.
 
[32]  Li L, Zhang J, Liu X, Li X, Jiao B, Kang T. “Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: A meta-analysis,” J Gastroenterol Hepatol, 27(1), 51-58. 2012.
 
Show Less References

Article

The Effect of Local Regional Therapy on Post-transplantation Survival Rate in Patients with Hepatocellular Carcinoma

1Department of General Surgery, Hospital of traditional Chinese medicine of Yubei, Chongqing, 400010, China

2Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China

3Department of Hepatobiliary Surgery, Suining Central Hospital, Suining 629000, China


American Journal of Cancer Prevention. 2016, 4(1), 18-22
doi: 10.12691/ajcp-4-1-4
Copyright © 2016 Science and Education Publishing

Cite this paper:
Wei Chen, Xiaoli Yang, Yakun Wu. The Effect of Local Regional Therapy on Post-transplantation Survival Rate in Patients with Hepatocellular Carcinoma. American Journal of Cancer Prevention. 2016; 4(1):18-22. doi: 10.12691/ajcp-4-1-4.

Correspondence to: Yakun  Wu, Department of Hepatobiliary Surgery, Suining Central Hospital, Suining 629000, China. Email: 353827514@qq.coml

Abstract

Background and Objective: This study aims to use meta-analysis to evaluate whether pre-transplantation local regional therapy (LRT) can improve the survival of patients with hepatocellular carcinoma who accepted liver transplantation. Methods: Relevant studies were identified by searching PUBMED, EMBASE and Web of Science Datebases up to May 2015. Endpoints were 1 year, 3 years, and 5 years survival rate after liver transplantation. Results: Analysis of nine retrospective studies including 1097 patients did not reveal significant difference in 1year, 3 years and 5 years survival rate between the patients who got LRT or not. Analysis of four retrospective studies including 504 patients showed patients with complete response to LRT have higher 5 years survival rate. Conclusions: The results of this meta-analysis suggest that the patients with complete response to LRT have higher post-transplantation survival rate. But LRT before liver transplantation can’t improve the overall survival rate.

Keywords

References

[1]  Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, “Global cancer statistics”, CA Cancer J Clin,61(2):69-90, Mar-Apr 2011.
 
[2]  Duan C, Liu M, Zhang Z, Ma K, Bie P, “Radiofrequency ablation versus hepatic resection for the treatment of early-stage hepatocellular carcinoma meeting Milan criteria: a systematic review and meta-analysis”, World J Surg Oncol,11 (1):190-199, Aug 2013.
 
[3]  Forner A1, Reig ME, de Lope CR, Bruix J, “Current strategy for staging and treatment: the BCLC update and future prospects”, Semin Liver Dis, 30(1):61-74, Feb 2010.
 
[4]  Sourianarayanane A, El-Gazzaz G, Sanabria JR, Menon KV, Quintini C, Hashimoto K, Kelly D, Eghtesad B, Miller C, Fung J, Aucejo F, “Loco-regional therapy in patients with Milan Criteria-compliant hepatocellular carcinoma and short waitlist time to transplant: an outcome analysis”. HPB (Oxford),14(5):325-32, May 2012.
 
[5]  Kim PT, Onaca N, Chinnakotla S, Davis GL, Jennings LW, McKenna GJ, Ruiz RM, Levy MF, Goldstein R, Klintmalm GB, “Tumor biology and pre-transplant locoregional treatments determine outcomes in patients with T3 hepatocellular carcinoma undergoing liver transplantation”, Clin Transplant, 27(2):311-8, Mar-Apr 2013.
 
Show More References
[6]  Bharat A, Brown DB, Crippin JS, Gould JE, Lowell JA, Shenoy S, Desai NM, Chapman WC, “Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival”, J Am Coll Surg 203(4):411-20, Oct 2006.
 
[7]  Cucchetti A, Cescon M, Bigonzi E, Piscaglia F, Golfieri R, Ercolani G, Cristina Morelli M, Ravaioli M, Daniele Pinna A, “Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy”, Liver Transpl, 17 (11):1344-54. Nov 2011.
 
[8]  Bargellini I, Vignali C, Cioni R, Petruzzi P, Cicorelli A, Campani D, De Simone P, Filipponi F, Bartolozzi C, “Hepatocellular carcinoma: CT for tumor response after transarterial chemoembolization in patients exceeding Milan criteria--selection parameter for liver transplantation”, Radiology, 255 (1):289-300, Apr 2010.
 
[9]  Millonig G, Graziadei IW, Freund MC, Jaschke W, Stadlmann S, Ladurner R, Margreiter R, Vogel W, “Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma” Liver Transpl, 13(2):272-9, Feb 2007.
 
[10]  Allard MA, Sebagh M, Ruiz A, Guettier C, Paule B, Vibert E, Cunha AS, Cherqui D, Samuel D, Bismuth H, Castaing D, Adam R, “Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation?” J Hepatol, 63(1):83-92, Jul 2015.
 
[11]  Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS, “Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria”, J Clin Oncol, 25(13):1753-1759, May 2007.
 
[12]  Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verwei J, “New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)”, Eur J Cancer, 45(2):228–247, Jan 2009.
 
[13]  Eswaran SL, Pierce K, Weaver F, Rogers T, Brems JJ, Sontag SJ, Borge M, “Transarterial chemoembolization for HCC in patients with extensive liver transplantation waiting times”, Angiology, 63(3):206-12, Apr 2012.
 
[14]  DuBay DA, Sandroussi C, Kachura JR, Ho CS, Beecroft JR, Vollmer CM, Ghanekar A, Guba M, Cattral MS, McGilvray ID, Grant DR, Greig PD, “Radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation”, HPB (Oxford), 13(1):24-32, Jan 2011.
 
[15]  Heckman JT, Devera MB, Marsh JW, Fontes P, Amesur NB, Holloway SE, Nalesnik M, Geller DA, Steel JL, Gamblin TC, “Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation”, Ann Surg Oncol, 15(11):3169-77. Nov 2008.
 
[16]  Maluf DG, Stravitz RT, Williams B, Cotterell AH, Mas VR, Heuman D, Luketic V, Shiffman ML, Sterling R, Posner MP, Fisher RA, “Multimodality therapy and liver transplantation in patients with cirrhosis and hepatocellular carcinoma: 6 years, single-center experience”, Transplant Proc, 39(1):153-9, Jan-Feb 2007.
 
[17]  Stockland AH, Walser EM, Paz-Fumagalli R, McKinney JM, May GR, “Preoperative chemoembolization in patients with hepatocellular carcinoma undergoing liver transplantation: influence of emergent versus elective procedures on patient survival and tumor recurrence rate”, Cardiovasc Intervent Radiol 30(5):888-93, Sep-Oct 2007.
 
[18]  Pérez SB, Meneu JC, Moreno E, García I, Moreno A, Fundora Y, “Is transarterial chemoembolization necessary before liver transplantation for hepatocellular carcinoma?” Am J Surg 190 (3):383-7, Sep 2005.
 
[19]  Decaens T, Roudot-Thoraval F, Bresson-Hadni S, Meyer C, Gugenheim J, Durand F, Bernard PH, Boillot O, Boudjema K, Calmus Y, Hardwigsen J, Ducerf C, Pageaux GP, Dharancy S, Chazouilleres O, Dhumeaux D, Cherqui D, Duvoux C, “Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma”, Liver Transpl, 11(7):767-75, Jul 2005.
 
[20]  Graziadei IW, Sandmueller H, Waldenberger P, Koenigsrainer A, Nachbaur K, Jaschke W, Margreiter R, Vogel W, “Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome”, Liver Transpl 9(6):557-63, Jun 2003.
 
[21]  Shillcutt SK, Ringenberg KJ, Chacon MM, Brakke TR, Montzingo CR, Lyden ER, Schulte TE, Porter TR, Lisco SJ, “Liver Transplantation: Intraoperative Transesophageal Echocardiography Findings and Relationship to Major Postoperative Adverse Cardiac Events”, J Cardiothorac Vasc Anesth 30(1):107-14, Jan 2016.
 
Show Less References

Article

Role of TACE in Patients with Hepatocellular Carcinoma before Liver Transplantation

1Department of General Surgery, The Thirteenth People's Hospital of Chongqing, Chongqing 400010, China

2Department of Hepatobiliary Surgery, Suining Central Hospital, Suining 629000, China


American Journal of Cancer Prevention. 2016, 4(2), 23-25
doi: 10.12691/ajcp-4-2-1
Copyright © 2016 Science and Education Publishing

Cite this paper:
Cheng Luo, Yakun Wu, Shaoyong Liang. Role of TACE in Patients with Hepatocellular Carcinoma before Liver Transplantation. American Journal of Cancer Prevention. 2016; 4(2):23-25. doi: 10.12691/ajcp-4-2-1.

Correspondence to: Shaoyong  Liang, Department of General Surgery, The Thirteenth People's Hospital of Chongqing, Chongqing 400010, China. Email: 353827514@qq.com

Abstract

Transarterial chemoembolization (TACE) can prevent tumor progression in patients with hepatocellular carcinoma awaiting liver transplantation. This article introduces the effect of TACE before liver transplantation in terms of dropout rate, improvement in overall survival, prediction of survival, and its application as down-stage therapy.

Keywords

References

[1]  Blackburn H, West S. Management of Postembolization Syndrome Following Hepatic Transarterial Chemoembolization for Primary or Metastatic Liver Cancer. Cancer Nurs. 2015 Oct 19. [Epub ahead of print].
 
[2]  Nicolini D, Svegliati-Baroni G, Candelari R, Mincarelli C, Mandolesi A, Bearzi I,et al. “Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation”. World J Gastroenterol 19(34): 5622-5632, Sep 2013.
 
[3]  Cucchetti A, Cescon M, Bigonzi E, Piscaglia F, Golfieri R, Ercolani G,et al. “Priority of Candidates With Hepatocellular Carcinoma Awaiting Liver Transplantation Can Be Reduced After Successful Bridge Therapy”, Liver Transpl 17(11):1344-1354, Nov 2011.
 
[4]  Fisher RA, Cotterell AH, Maluf DG, Stravitz RT, Ashworth A, Nakatsuka M, et al. “Adult living donor versus deceased donor liver transplantation:A 10-year prospective single center experience”, Annal of Hepatology 8(4):298-307. Oct 2009.
 
[5]  Park SJ, Freise CE, Hirose R, Kerlan RK, Yao FY, Roberts JP, et al. “Risk factors for liver transplant waitlist dropout in patients with hepatocellular carcinoma”.Clin Transplant, 26(4):359-364, Jul 2012.
 
Show More References
[6]  Fujiki M, Aucejo F, Kim R. “General overview of neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: necessity or option? Liver Int 31(8): 1081-1089, Sep 2011.
 
[7]  Pompili M, Francica G, Ponziani FR, Iezzi R, Avolio AW. “Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation”. World J Gastroenterol 19(43): 7515-7530 Nov 2013.
 
[8]  Millonig G, Graziadei IW, Freund MC, Jaschke W, Stadlmann S, Ladurner R, et al. “Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma”. Liver Transpl 13(2):272-9, Feb 2007.
 
[9]  Decaens T, Roudot-Thoraval F, Bresson-Hadni S, MeyerC, Gugenheim J, Durand F, et al. “Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma”. Liver Transpl 11(7): 767-775, Jul 2005.
 
[10]  Bharat A, Brown DB, Crippin JS, Gould JE, Lowell JA, Shenoy S, et al. “Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival”. J Am Coll Surg 203(4): 411-420, Oct 2006.
 
[11]  Cescon M, Cucchetti A, Ravaioli M, Pinna AD. “Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplant ability and recurrence rate”. J Hepatol 58(3): 609-618, Mar 2013.
 
[12]  Tsochatzis E, Garcovich M, Marelli L, Papastergiou V, Fatourou E, Rodriguez Peralvarez ML et al. “Transarterial chemoembolization as neo-adjuvant therapy pre-transplantation in patients with hepatocellular carcinoma”. Liver Int. 33(6):944-949, Jul 2013.
 
[13]  Eswaran SL, Pierce K, Weaver F, Rogers T, Brems JJ, Sontag SJ, et al. “Transarterial Chemoembolization for HCC in Patients With Extensive Liver Transplantation Waiting Times”. Angiology 63(3):206-12, Apr 2012.
 
[14]  Vivanco M, Gabrielli M, Jarufe N, Humeres R, Rios H, Palacios JM, et al. “Bridge therapy in hepatocellular carcinoma before liver transplantation: the experience of two Chilean centers”. Transplant Proc 42(1):296-304 Jan 2010.
 
[15]  Cotoi CG, Khorsandi SE, Pleşea IE, Quaglia A. “Histological aspects of post-TACE hepatocellular carcinoma”. Rom J Morphol Embryol 53(3): 677-682, 2012.
 
[16]  Otto G, Schuchmann M, Hoppe-Lotichius M, Heise M, Weinmann A, Hansen T. “How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions rresponse to TACE?” J Hepatol 59(2): 279-284. Aug 2013.
 
[17]  Chan KM, Yu MC, Chou HS, Wu TJ, Lee CF, Lee WC. “Significance of Tumor Necrosis for Outcome of Patients with Hepatocellular Carcinoma Receiving Locoregional Therapy Prior to Liver Transplantation”. Ann Surg Oncol 18(9): 2416-2426. Sep 2011.
 
[18]  Bargellini I, Vignali C, Cioni R, Petruzzi P, Cicorelli A, Campani D, et al. “Hepatocellular Carcinoma: CT for Tumor Response after Transarterial Chemoembolization in Patients Exceeding Milan Criteria—Selection Parameter for Liver Transplantation”. Radiology. 255(1):289-300, Apr 2010.
 
[19]  Bouchard-Fortier A, Lapointe R, Perreault P, Bouchard L, Pomier-Layrargues G. “Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma as a Bridge to Liver Transplantation: A Retrospective Study”. Int J Hepatol. 974514, Jan 2011.
 
[20]  Schaudt A, Kriener S, Schwarz W, Wullstein C, Zangos S, Vogl T, et al. “Role of transarterial chemoembolization for hepatocellular carcinoma before liver transplantation with special consideration of tumor necrosis”. Clin Transplant 23(21): 61-67, Dec 2009.
 
[21]  Majno P, Lencioni R, Mornex F, Girard N, Poon RT, Cherqui D. “Is the Treatment of Hepatocellular Carcinoma on the Waiting List Necessary?” Liver Transpl 17:S98-108, Oct 2011.
 
[22]  Gordon-Weeks AN, Snaith A, Petrinic T, Friend PJ, Burls A, Silva MA. “Systematic review of outcome of downstaging hepatocellular cancer before liver transplantation in patients outside the Milan criteria”. Br J Surg 98(9): 1201-1208, Sep 2011.
 
[23]  Chapman WC , Majella Doyle MB , Stuart JE , Vachharajani N , Crippin JS , Anderson CD, et al. “Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation”. Annals of surgery 248(4):617-642, Oct 2008.
 
Show Less References